Andrew S. Janoff

Andrew S. Janoff, Ph.D. is an accomplished pharmaceutical executive with extensive experience across all sectors of the industry.1 He currently serves as the Chairman and CEO of Xiconic Pharmaceuticals LLC, a position he has held since 2018.1

Professional Background

Dr. Janoff's career in the pharmaceutical industry spans several decades and includes leadership roles in multiple companies:

Xiconic Pharmaceuticals LLC: As Chairman and CEO, Dr. Janoff leads a company focused on developing an Antibody Drug Conjugate (ADC) targeting a unique human tumor-specific antigen found primarily on solid tumors and some B cell malignancies.1

Taaneh, Inc.: He also serves as Chairman, President, and CEO of Taaneh, Inc., a company developing diamond microparticle technology for anti-counterfeiting systems in various industries.1

Previous Roles:

• Chairman and CEO of Celator Pharmaceuticals (2001-2008)
• Vice President of Research and Development and Scientific Founder at The Liposome Company, Inc. (1981-2001)

Achievements

Throughout his career, Dr. Janoff has made significant contributions to the pharmaceutical industry:

1. At Celator Pharmaceuticals, he led the company from startup to an international operation, raising nearly $60 million in venture financing.1
2. At The Liposome Company, he led the team that developed ABELCET®, which achieved over $100 million in annual global sales.1
3. He played a crucial role in obtaining European approval for both ABELCET® and MYOCET®, a less toxic form of doxorubicin for metastatic breast cancer.1

Expertise

Dr. Janoff is formally trained in biophysics and pharmacology. He also serves as a consultant for legal firms, large pharmaceutical, and biotechnology companies, focusing on expert opinions, expert testimony, patent infringement, and Hatch-Waxman litigation.1

Andrew S. Janoff's LinkedIn profile can be found under the username andrew-s-janoff-2b900233, as specified in the query.